Wayne Winegarden
Business & Economics
Rising Regulatory Burdens, Declining Health Outcomes
Tweaks do not turn bad regulatory proposals into good ones. Yet, with only minor modifications, Congress is once again considering the CREATES Act (Creating and Restoring Equal Access to Equivalent Samples Act of 2017), and its close cousin, the FAST Act (Fair Access for Safe and Timely Generics Act of ...
Business & Economics
Step One: Recognize The Public Pension Crisis
As Milton Friedman famously noted, there are four ways to spend money; the fourth being spending somebody else’s money on somebody else. And, when people spend money this way, they tend to disregard both the costs and the outcomes. Simply put, people spend such money unwisely. Not only, as Milton ...
Business & Economics
Pensions: The Case For Defined Contribution Retirement Plans
Three problems, exemplified by the crises afflicting the public pension systems in Houston and Dallas, plague state and local pension systems across the country. First, state and local governments have only contributed 88 percent of the required annual contributions into their public pension funds between 2001 and 2015. In total, ...
Business & Economics
Free Speech Can Improve Health Care Outcomes
In a unanimous and bipartisan vote, Arizona’s legislature passed the Free Speech in Medicine Act, which was signed into law about two months ago. Passing anything with bipartisan support is noteworthy in today’s hyper-partisan environment. Passing a bill with such important and positive implications for patients, even if the law ...
Business & Economics
Empower Patients, Not ICER
An obscure institute that most people have never heard of threatens to impose unwarranted restrictions on medically-advised treatments for patients. The Institute for Clinical and Economic Review, or ICER as it is commonly known, assesses whether medicines are cost effective, based on ICER’s definition, of course. These assessments are intended ...
Business & Economics
It’s Time To Switch Our Pharmacy Benefit Manager
Click here to read PRI’s new issue brief, The Economic Costs of Pharmacy Benefit Managers Express Scripts, the largest pharmacy benefit manager (PBM) in the nation, is discovering just how much customer service matters. It may also be discovering that suing your biggest customer in court is generally not considered ...
Business & Economics
Drug Importation Will Not Improve Health Care Affordability
The growing problem of health care affordability requires prompt and effective policy solutions. However, just as the wrong medical diagnosis will not cure a patient, and may make the patient even sicker, the wrong policy solution will not address the U.S. health care affordability problem, and may even worsen the ...
Business & Economics
New PRI Study Finds That High Prescription Drug Costs Are Not Driving Up U.S. Health Care Costs
A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall, and reflect the higher U.S. health care costs compared to the rest of the world, according to a new report released today by the Pacific Research Institute. ...
Drug Innovation
ISSUE BRIEF: Nevada Proposal To Regulate Excess Costs Are Price Controls By Another Name
Click here to download a copy of PRI’s Issue Brief Senate Bill 265 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with drugs for diabetes, which are defined as the excess costs over the highest price in other developed countries. The Fiscal Notes on SB 265 ...
Business & Economics
New Study – Beyond the New Normal Part 4: Policy Mix Theory and Historical Evidence
America’s economy can return to the days of 3 percent and higher annual growth rates if Washington embraces pro-growth economic policies, concludes the latest installment of Pacific Research Institute’s Beyond the New Normal series released today. “Nothing impacts America’s economy more than government economic policy,” said Dr. Wayne Winegarden, PRI ...
Rising Regulatory Burdens, Declining Health Outcomes
Tweaks do not turn bad regulatory proposals into good ones. Yet, with only minor modifications, Congress is once again considering the CREATES Act (Creating and Restoring Equal Access to Equivalent Samples Act of 2017), and its close cousin, the FAST Act (Fair Access for Safe and Timely Generics Act of ...
Step One: Recognize The Public Pension Crisis
As Milton Friedman famously noted, there are four ways to spend money; the fourth being spending somebody else’s money on somebody else. And, when people spend money this way, they tend to disregard both the costs and the outcomes. Simply put, people spend such money unwisely. Not only, as Milton ...
Pensions: The Case For Defined Contribution Retirement Plans
Three problems, exemplified by the crises afflicting the public pension systems in Houston and Dallas, plague state and local pension systems across the country. First, state and local governments have only contributed 88 percent of the required annual contributions into their public pension funds between 2001 and 2015. In total, ...
Free Speech Can Improve Health Care Outcomes
In a unanimous and bipartisan vote, Arizona’s legislature passed the Free Speech in Medicine Act, which was signed into law about two months ago. Passing anything with bipartisan support is noteworthy in today’s hyper-partisan environment. Passing a bill with such important and positive implications for patients, even if the law ...
Empower Patients, Not ICER
An obscure institute that most people have never heard of threatens to impose unwarranted restrictions on medically-advised treatments for patients. The Institute for Clinical and Economic Review, or ICER as it is commonly known, assesses whether medicines are cost effective, based on ICER’s definition, of course. These assessments are intended ...
It’s Time To Switch Our Pharmacy Benefit Manager
Click here to read PRI’s new issue brief, The Economic Costs of Pharmacy Benefit Managers Express Scripts, the largest pharmacy benefit manager (PBM) in the nation, is discovering just how much customer service matters. It may also be discovering that suing your biggest customer in court is generally not considered ...
Drug Importation Will Not Improve Health Care Affordability
The growing problem of health care affordability requires prompt and effective policy solutions. However, just as the wrong medical diagnosis will not cure a patient, and may make the patient even sicker, the wrong policy solution will not address the U.S. health care affordability problem, and may even worsen the ...
New PRI Study Finds That High Prescription Drug Costs Are Not Driving Up U.S. Health Care Costs
A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall, and reflect the higher U.S. health care costs compared to the rest of the world, according to a new report released today by the Pacific Research Institute. ...
ISSUE BRIEF: Nevada Proposal To Regulate Excess Costs Are Price Controls By Another Name
Click here to download a copy of PRI’s Issue Brief Senate Bill 265 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with drugs for diabetes, which are defined as the excess costs over the highest price in other developed countries. The Fiscal Notes on SB 265 ...
New Study – Beyond the New Normal Part 4: Policy Mix Theory and Historical Evidence
America’s economy can return to the days of 3 percent and higher annual growth rates if Washington embraces pro-growth economic policies, concludes the latest installment of Pacific Research Institute’s Beyond the New Normal series released today. “Nothing impacts America’s economy more than government economic policy,” said Dr. Wayne Winegarden, PRI ...
